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EDITORIAL COMMENT
Platelets and the Endothelium
Active Participants in Severe COVID-19 Infection*
William A.E. Parker, MBBCHIR,a,b Robert F. Storey, MD, DMa,b
T
he coronavirus disease 2019 (COVID-19)
pandemic currently gripping the planet is
presenting the biggest acute public health
crisis in generations, impacting not only physical
well-being but also exerting huge social, economic,
and organizational pressure, and diverting resources
and attention from other life-threatening conditions.
Although the initial phase of infection with severe
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is typically mild, a significant proportion of
patients go on to experience severe COVID-19, charac-
terized by pneumonitis and a systemic inflammatory
response that can lead to multiorgan failure and
death. Beyond prevention with public health inter-
ventions, key to tackling the disease is gaining an
awareness and understanding of the underlying path-
ophysiology, in terms of the infection itself and the
host response. Identifying prominent actors in these
processes can help find candidate treatments.
It is now established that severe COVID-19 is
associated with significant increases in a range of
cytokines, including interleukin-6 (IL-6) (1). It is also
clear that microthrombosis and macrothrombosis
contribute significantly as pathological mechanisms.
This can manifest as, for example, microvascular
dysfunction, pulmonary emboli, or disseminated
intravascular coagulation, and an increased risk of
atherothrombotic events, such as acute myocardial
infarction and ischemic stroke. Furthermore, a strong
association between pre-existing cardiovascular dis-
ease and outcomes from severe COVID-19 raised hy-
potheses about shared mechanisms.
Now, in this issue of JACC: Basic to Translational
Science, Canzano et al. (2) provide valuable and
detailed insights into platelet and endothelial func-
tion during COVID-19, including stratification by
severity of the illness. The authors, based in Milan,
Italy, the early epicenter of the pandemic in Europe,
should be congratulated for undertaking this work in
such challenging conditions.
Through a series of elegant studies including direct
measurements and incorporation of samples into
in vitro models from patients with COVID-19, they
paint a picture of profound dysregulation of platelets
and the endothelium, fueled by an intense inflam-
matory response.
Four main processes of particular significance are
identified. First, IL-6 seems to be a key cytokine
driving platelet hyperreactivity in COVID-19 infec-
tion. Although in this study the mechanism for this
observation was not fully determined, recent reports
have suggested that IL-6 signaling may stimulate
platelets via interaction with the platelet collagen
receptor glycoprotein VI (3). Furthermore, a mono-
clonal antibody against IL-6, tocilizumab, seemed to
abrogate these effects, and there is growing evidence
this agent may improve clinical outcomes.
Second, platelet-derived microvesicles containing
tissue factor seem critical. Tissue factor activates
factor VII and therefore the extrinsic pathway of the
coagulation cascade, resulting in generation of
thrombin that cleaves soluble fibrinogen to insoluble
fibrin and activates platelets via protease-associated
receptors 1 and 4 (4). In this study, prophylactic or
therapeutic levels of low-molecular-weight heparin
were unable to adequately suppress thrombin
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generation, suggesting that more potent or broad
antithrombotic therapy may be needed to halt this
process.
Third, increased levels of platelet-leukocyte ag-
gregates observed during COVID-19 infection under-
line the role that activated platelets play in directly
stimulating inflammatory cell function. These form
via platelet surface expression of P-selectin, con-
tained within a-granules that fuse with the cell
membrane on platelet activation, binding to leuko-
cyte P-selectin glycoprotein ligand-1 (4).
Finally, endothelial dysfunction clearly plays a
role. Depletion of nitric oxide (NO), an inhibitor of
platelet activation and anti-inflammatory at normal
physiological concentrations, was observed. There
was also evidence of increased endothelial prostacy-
clin (PGI2). Although the balance of benefits and
harms of PGI2 in acute inflammation remain to be
fully explored, it is clear that, although it acts to
inhibit platelet activation, PGI2 also leads to vaso-
diliation that, if excessive, may contribute to circu-
latory collapse.
No doubt there are other responsible mechanisms,
including such systemic factors as increased circu-
lating catecholamines and serotonin, which may in-
crease platelet reactivity. The fact that samples in this
study were negative for the virus mean any direct
effect of SARS-CoV-2 on platelets and the endothe-
lium has not been assessed here. Although it remains
contentious, there is some evidence from other work
that the virus binding to platelet angiotensin con-
verting enzyme-2 may contribute to activation.
What implications do these findings have for
treatment of COVID-19? As well as direct targeting
of the inflammatory response, it is logical to
consider what antithrombotic therapy might be of
benefit during COVID-19 infection. In the absence of
confirmed venous thromboembolism, only heparin
(low-molecular-weight heparin or unfractionated) at
subtherapeutic doses is currently recommended (1),
but the findings of this study may support the
investigation of more intense routine anti-
coagulation. Considering the apparently prominent
role of platelets in COVID-19, antiplatelet therapy
may also be rational. The most common antiplatelet
agents available are the cyclooxygenase inhibitor
aspirin and oral P2Y12 inhibitors, such as the thie-
nopyridines clopidogrel and prasugrel, and the
cyclopentyl-triazolopyrimidine ticagrelor (4). Among
the P2Y12 inhibitors, clopidogrel is less potent and
reliable than prasugrel and ticagrelor. However,
subtleties in the effects of each agent may hypo-
thetically influence overall benefits and risk in se-
vere COVID-19.
For example, there is convincing evidence that
P2Y12 inhibition significantly inhibits platelet P-
selectin expression. Although Canzano et al. (2) also
show that aspirin reduced platelet P-selectin expres-
sion in vitro, this has not been reliably shown in
clinical studies outside the setting of COVID-19, and it
remains clear that any ability of aspirin to inhibit this
is much less than that of P2Y12 inhibition.
Pleiotropic effects also need to be considered.
Aspirin may counteractively potentiate the inflam-
matory response, crucially increasing plasma IL-6
during states, such as endotoxemia, in contrast to
P2Y12 inhibitors that reduce it (1). Ticagrelor, but not
other P2Y12 inhibitors, potentiates adenosine-induced
stimulation of neutrophil chemotaxis and phagocy-
tosis via local inhibition of adenosine uptake through
equilibrative nucleoside transporter-1 on erythro-
cytes and platelets, whereas clopidogrel may have an
effect of reducing circulating leukocyte count and
cytokines, such as IL-6, compared with ticagrelor.
However, both aspirin and ticagrelor, but not the
other agents, may theoretically counteract endothe-
lial NO depletion (5). Aspirin may increase NO avail-
ability via mechanisms, such as acetylation of
endothelial NO synthase (eNOS); increasing the ac-
tivity of dimethylarginine-dimethylaminohydrolase,
responsible for degrading the endogenous eNOS in-
hibitor asymmetric dimethylarginine; and generation
of 15-epi lipoxin A4, which increases eNOS activity.
Ticagrelor, but not other P2Y12 inhibitors, may also
increase NO generation, adenosine having the effect
of increasing eNOS activity. High but not low doses of
aspirin inhibit PGI2 generation, whereas ticagrelor
may theoretically upregulate it via an adenosine-
dependent mechanism. How these divergent effects
translate into influencing the course of severe COVID-
19 remain undetermined.
Any benefits of initiation or intensification of
antithrombotic therapy need to be balanced
against associated increases in bleeding risk through
study of clinical outcomes and data should soon be
available from trials including regimens of antith-
rombotic therapy. Therapeutic anticoagulation is
included in an arm of the ongoing REMAP-CAP
(Randomized, Embedded, Multifactorial Adaptive
Platform Trial for Community-Acquired Pneumonia)
study (NCT02735707), which is also studying the ef-
fects of single antiplatelet therapy with either aspirin
or a P2Y12 inhibitor. Similarly, the RECOVERY (Ran-
domized Evaluation of COVID-19 Therapy) trial
(NCT04381936) is including aspirin as a treatment
allocation. In practice, development of thrombocy-
topenia or deranged clotting parameters is common
during severe COVID-19 and this may dissuade
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clinicians from initiating antithrombotic therapy.
However, because these abnormalities are typically
caused by overconsumption of platelets and clotting
factors, respectively, early initiation may be rational
even in this difficult situation. Whether multiple
versus single agent antithrombotic therapy is supe-
rior in COVID-19 remains largely unexplored.
Beyond COVID-19, how can one apply these find-
ings? Such is the nature of human ingenuity in the
face of adversity, global crises often lead to rapid
progression in technology driven by necessity and
targeted investment. Developments can typically be
exploited for further benefit once the acute problem
is overcome. Looking for any silver lining of the cur-
rent predicament, perhaps through the intense
research being carried out into COVID-19, we can
hope that at least advances will be made of more
broad relevance to other intense inflammatory states,
such as sepsis, and even to more chronic conditions,
such as atheroinflammation. What remains clear,
however, is the logical way out of this unhappy global
experience is the continued pursuit of scientific
knowledge and fruitful collaboration toward a com-
mon goal of overcoming COVID-19.
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